{
    "clinical_study": {
        "@rank": "78782", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "Panitumumab plus DCF"
        }, 
        "brief_summary": {
            "textblock": "Investigators propose to study the effect of panitumumab when combined with an active\n      regimen, such as DCF (Docetaxel/Cisplatin/Fluourouracil), in previously untreated patients\n      with advanced cancer of the stomach."
        }, 
        "brief_title": "Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Investigators propose a phase I/II study in order to evaluate the effect of panitumumab when\n      combined with an active regimen, such as DCF (Docetaxel/Cisplatin/Fluourouracil), in\n      chemotherapy - naive patients with advanced cancer of the stomach.\n\n      Investigators hypothesize that the addition of panitumumab to DCF regimen in advanced cancer\n      of the stomach and gastroesophageal junction is feasible, well tolerated and could achieve\n      an objective response rate of greater than 40%.\n\n      The 2-weekly schedule of DCF will be used as chemotherapy since a recently presented trial\n      demonstrated a comparable efficacy but a more favourable toxicity profile comparable to the\n      3-weekly schedule."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven inoperable locally advanced or metastatic adenocarcinoma of the\n             stomach (including adenocarcinoma of the gastrooesophageal junction)\n\n          -  Patient's age between 20 and 70 years old\n\n          -  Measurable disease defined by RECIST criteria\n\n          -  Patients with non-measurable disease could be enrolled in the phase I part of the\n             study\n\n          -  ECOG performance status \u2264 1\n\n          -  Hgb \u2265 8g/dL, WBC \u2265 3 x 109/L , neutrophils count \u2265 1.5 x 109/L ,  platelets \u2265100 x\n             109/L, Creatinine clearance \u226550 mL/min, Total bilirubin \u2264 1.5 X UNL, AST, ALT and ALP\n             \u2264 2.5 x UNL\n\n          -  No prior chemotherapy or more than 6 months from adjuvant chemotherapy or\n             chemo-radiation\n\n          -  Estimated life expectancy more than 3 months\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Gastrointestinal bleeding\n\n          -  Clinically relevant, symptomatic excessive amounts of ascites resulting in patient's\n             discomfort\n\n          -  CNS metastases\n\n          -  History of hypersensitivity to fluoropyrimidines, docetaxel or platinum compounds\n\n          -  Any previous chemotherapy or radiotherapy for advanced disease\n\n          -  Patient pregnant or breast feeding, or planning to become pregnant within 6 months\n             after the end of treatment\n\n          -  Patient (male or female) is not willing to use highly effective methods of\n             contraception (per institutional standard) during treatment and for 6 months (male or\n             female) after the end of treatment\n\n          -  Known hypersensitivity reaction to the component of the treatment\n\n          -  Active infection or malnutrition or bowel obstruction\n\n          -  Legal incapacity or limited legal capacity\n\n          -  Definite contraindications for the use of corticosteroids\n\n          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or\n             evidence of interstitial lung disease on baseline chest CT scan\n\n          -  Chronic inflammation of the bowel\n\n          -  Clinically significant cardiovascular disease (including myocardial infarction,\n             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac\n             arrhythmia) \u2264 1 year before enrollment\n\n          -  Medical or psychological condition which in the opinion of the investigator would not\n             permit the subject to complete the study or sign meaningful informed consent\n\n          -  A second primary tumor other than non-melanoma skin cancer or in situ cervical cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716546", 
            "org_study_id": "CT/09.10"
        }, 
        "intervention": {
            "arm_group_label": "1", 
            "intervention_name": "Pazopanib", 
            "intervention_type": "Drug", 
            "other_name": "Pazopanib: 800mg once a day for up to 2 years from date of first dose"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced cancer of the stomach", 
            "Chemotherapy - naive patients", 
            "DCF"
        ], 
        "lastchanged_date": "September 14, 2013", 
        "location": [
            {
                "contact": {
                    "email": "nikos251@yahoo.gr", 
                    "last_name": "Nikos Fytrakis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Air Forces Military Hospital of Athens"
                }, 
                "investigator": [
                    {
                        "last_name": "Nikos Kentepozidis, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Nikos Fytrakis, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christofyll@yahoo.gr", 
                    "last_name": "Charalampos Christofyllakis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "401 Military Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Charalampos Christofyllakis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stylianos Giassas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "\"IASO\" General Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Stylianos Giassas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "p_koliou@hotmail.com", 
                    "last_name": "Panagiotis Koliou, MD", 
                    "phone": "+306973375489"
                }, 
                "facility": {
                    "address": {
                        "city": "Chania", 
                        "country": "Greece"
                    }, 
                    "name": "\"Ag.Georgios\" General Hospital of Chania"
                }, 
                "investigator": [
                    {
                        "last_name": "Ioannis Varthalitis, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Panagiotis Koliou, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marina.st.nurse@gmail.com", 
                    "last_name": "Marina Maurogianni", 
                    "phone": "+302810392091"
                }, 
                "facility": {
                    "address": {
                        "city": "Heraklion", 
                        "country": "Greece"
                    }, 
                    "name": "University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece"
                }, 
                "investigator": {
                    "last_name": "Vassilis Georgoulias, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "athanasiadis.athanasios@gmail.com", 
                    "last_name": "Athanasios Athanasiadis, MD", 
                    "phone": "+306944521400"
                }, 
                "facility": {
                    "address": {
                        "city": "Larissa", 
                        "country": "Greece"
                    }, 
                    "name": "State General Hospital of Larissa"
                }, 
                "investigator": {
                    "last_name": "Athanasios Athanasiadis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alexandra Karadima, MD", 
                    "phone": "+306975206026"
                }, 
                "facility": {
                    "address": {
                        "city": "Piraeus", 
                        "country": "Greece"
                    }, 
                    "name": "\"Metaxa's\" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology"
                }, 
                "investigator": [
                    {
                        "last_name": "Nikolaos Ziras, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alexandra Karadima, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Mperedimou", 
                    "phone": "+302310400489"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "Diabalkaniko General Hospital of Thessaloniki"
                }, 
                "investigator": {
                    "last_name": "Christos Emmanouilidis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ibouk@otenet.gr", 
                    "last_name": "Ioannis Mpoukovinas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "\"Theagenion\" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Ioannis Mpoukovinas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II, Multicenter, Single-Arm Clinical Trial of Panitumumab in Combination With Cisplatin, Fluourouracil and Docetaxel (DCF) in Locally Advanced or Metastatic Cancer of the Stomach and Gastro-oesophageal Junction.", 
        "overall_contact": {
            "email": "agelaki@med.uoc.gr", 
            "last_name": "Sofia Aggelaki, MD", 
            "phone": "+302810392747"
        }, 
        "overall_contact_backup": {
            "email": "dorachat@med.uoc.gr", 
            "last_name": "Dora Chatzidaki", 
            "phone": "+302810392570"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: National Organization of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be followed for disease evaluation every eight (8) weeks from the first day of chemotherapy until the first documentation of disease progression", 
            "measure": "Objective response rate", 
            "safety_issue": "No", 
            "time_frame": "Every 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716546"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients will be evaluated from the date of the first chemotherapy cycle until the date of first documented progression or date of death from any cause, whichever came first", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Patients will be evaluated for overall survival from the date of the first chemotherapy cycle until the date of death from any cause", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Patients will be evaluated for toxicity profil on Day 1 of the first two chemotherapy cycle (cycle repeated every 2 weeks)", 
                "measure": "Maximum Tolerated Dose of the combination", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }
        ], 
        "source": "Hellenic Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hellenic Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}